ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2229

National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1889

Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2222

Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 1783

Nerve Growth Factor Causes Sensitization, Nociceptor Sprouting, Synovitis, And Osteophyte Formation In Naïve Murine Joints

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2278

Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2310

Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1874

Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 2078

Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2425

Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1815

New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential

(1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2076

Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1792

OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1794

OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2458

Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2200

Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].